In order to clarify the role of fatty acid metabolic enzyme SCD1 in the cancer-related immune response, we evaluated the immunologic antitumor effects of SCD1 inhibition and its mechanism using C57BL/6 and Balb/C mice implanted with four different types of syngeneic murine tumors, including MC38 colon cancer cells, CT26 colon cancer cells, MCA205 sarcoma cells and 4T1 breast cancer cells. The gene discussed is SCD; the disease is breast carcinoma.